Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 5/20 | 0.49 |
| ▸ | MTNR1B | P49286 | 5/20 | 0.49 |
| ▸ | ACACB | O00763 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | F13A1 | P00488 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20037794 | 0.83 | MTNR1A (0.48) | MTNR1AMTNR1BACACBKDM4EF13A1 | |
| SCHEMBL18291730 | 0.83 | NAMPT (0.50) | MTNR1AMTNR1BACACBKDM4EF13A1 | |
| SCHEMBL21339923 | 0.81 | ALDH1A1 (0.47) | MTNR1AACACBKDM4EF13A1ALDH1A1 | |
| SCHEMBL20249206 | 0.81 | MTNR1A (0.46) | MTNR1AMTNR1BACACBKDM4EF13A1 | |
| SCHEMBL14562256 | 0.76 | MTNR1A (0.58) | MTNR1AMTNR1BALDH1A1L3MBTL1SMN1; SMN2 | |
| SCHEMBL20162470 | 0.75 | EPHX2 (0.59) | MTNR1AMTNR1BALDH1A1L3MBTL1 | |
| SCHEMBL11554729 | 0.75 | KDM4E (0.58) | MTNR1AMTNR1BKDM4EF13A1ALDH1A1 | |
| SCHEMBL5987412 | 0.75 | KDM4E (0.58) | MTNR1AMTNR1BKDM4EF13A1ALDH1A1 | |
| SCHEMBL2167338 | 0.75 | KDM4E (0.79) | MTNR1AMTNR1BKDM4EF13A1ALDH1A1 | |
| SCHEMBL5987763 | 0.75 | KDM4E (0.58) | MTNR1AMTNR1BKDM4EF13A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6706885-B2 | HYDROGENATION OF PROTECTED 2,5-DI-(3'-AMINOPROP-1-YNYL) PYRIDINES AND DEPROTECTING TO FORM 2,5-DI-(3'-AMINOPROPYL)-PYRIDINES | MERCK & CO., INC. | 2004-03-16 | — | — | US | disclosed |
| US-20030004353-A1 | Process for preparing integrin antagonist intermediates | MERCK SHARP & DOHME CORP. | 2003-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030004353-A1 | Process for preparing integrin antagonist intermediates | ITGA5, ITGAV, ITGA2 | MTNR1A 2207/4885MTNR1B 2130/4885ACACB 4138/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.